.jpg){kind=logo}
Who We Are
We are an Oxford University spin-out improving neurology drug discovery by bringing more human data to the process. We are experts in developing, analysing and combining data from induced pluripotent stem cells, large scale genetics studies, and population health data. We identify and validate safe and effective drug targets for neurological diseases where current models aren't working. We work with pharmaceutical partners and on in-house programmes. We are backed by the major venture capital fund Oxford Science Enterprises.
Our Technology
Our approach combines three key technologies: genetically validated IPSC models that replicate disease states, genomic analysis showing the impact of disease and treatments across relevant tissue and patient groups, and retrospective analysis of population prescription and health data to illustrate safe and effective off-target impact.
